| answer text |
<p>The National Expert Working Group is one of the sources of clinical opinion to
develop clinical policies. During this period the RAPID C-19 cross-agency group was
also set up to review COVID-19 therapies in response to the pandemic. They would consider
evidence and analysis from a number of sources, including the Prophylaxis Oversight
Group and the UK Health Security Agency. In addition, the Therapeutics Clinical Review
Panel considered evidence for COVID-19 risk to help prioritise cohorts for prophylaxis.
This informed thinking within the Department and was subsequently shared with the
National Institute for Health and Care Excellence. These groups continued to consider
emerging evidence, including published evidence from independent researchers and evidence
from the company, after the last meeting of the Expert Working Group.</p>
|
 |
